Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 10/20 | 0.53 |
| ▸ | CTSK | P43235 | 10/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624247 | 0.90 | CTSL (0.54) | CTSLCTSKL3MBTL1CTSBMAPT | |
| SCHEMBL13624267 | 0.86 | CTSL (0.56) | CTSLCTSKL3MBTL1CTSBMAPT | |
| SCHEMBL13624266 | 0.85 | CTSL (0.60) | CTSLCTSKL3MBTL1CTSBMAPT | |
| SCHEMBL13624265 | 0.85 | CTSL (0.54) | CTSLCTSKL3MBTL1CTSBMAPT | |
| SCHEMBL13624264 | 0.84 | CTSL (0.53) | CTSLCTSKL3MBTL1CTSBSMN1; SMN2 | |
| SCHEMBL13624253 | 0.82 | L3MBTL1 (0.47) | CTSLCTSKL3MBTL1CTSBMAPT | |
| SCHEMBL30964173 | 0.79 | MAPT (0.71) | L3MBTL1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL30964184 | 0.77 | MAPT (0.68) | L3MBTL1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29551592 | 0.77 | ALDH1A1 (0.60) | MAPTSMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL13624252 | 0.75 | MAPT (0.47) | L3MBTL1MAPTSMN1; SMN2NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | CTSL 24/4885CTSK 15/4885L3MBTL1 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.